AML is an aggressive blood cancer in which abnormal myeloid cells accumulate in the bone marrow and interfere with the production of normal blood cells. Mutations in the gene encoding FLT3, a receptor tyrosine kinase that transmits growth and survival signals, are among the most common genetic alterations found in AML. These mutations can cause FLT3 to remain abnormally active, encouraging leukemia cells to multiply rapidly and resist normal controls on growth. Several drugs, including gilteritinib, have been developed to block mutant FLT3, but patients frequently experience treatment resistance or relapse.

“FLT3 mutations are one of the most common genetic drivers of AML,” said corresponding author Dr. Daisuke Nakada, Henry and Emma Meyer Professor in Molecular and Human Genetics at Baylor College of Medicine. Earlier work had established that FLT3 inhibition can stop leukemia cells from dividing and activate apoptosis, a programmed self-destruction pathway. Nakada and his colleagues investigated whether the drugs might also kill AML cells through a mechanism that does not depend solely on apoptosis. Their experiments revealed that the answer is ferroptosis, a distinct process that is increasingly recognized as an important vulnerability in cancer.

Ferroptosis occurs when cells lose the ability to control lipid peroxidation. In this process, reactive oxygen molecules attack polyunsaturated fatty acids within cellular membranes, generating unstable lipid compounds that damage membrane structure and disrupt essential cellular functions. Unlike apoptosis, which involves an organized dismantling of the cell, ferroptosis is associated with catastrophic oxidative injury. The researchers observed evidence of this process in mouse models, laboratory leukemia cell lines and patient-derived AML samples transplanted into animals, demonstrating that the mechanism was not restricted to a single experimental system.

The team traced the vulnerability to GPX4, an enzyme that protects cell membranes from lipid peroxidation. GPX4 is a selenoprotein, meaning that it contains the trace element selenium as part of its active structure. By reducing harmful lipid peroxides, GPX4 acts as one of the cell’s most important defenses against ferroptosis. The researchers found that mutant FLT3 supports the production of GPX4 and other selenoproteins in AML cells. When FLT3 is blocked, this production is disrupted, leaving leukemia cells increasingly exposed to oxidative damage.

According to the study, the effect is not simply a matter of FLT3 inhibitors switching off a growth signal. The drugs also appear to interfere with the cellular machinery required to make selenoproteins. As GPX4 levels fall, AML cells become less capable of neutralizing lipid peroxides. The resulting accumulation of oxidized lipids pushes the cells beyond a critical threshold, triggering ferroptotic death. This connection between mutant FLT3 signaling, selenium-dependent protein production and ferroptosis provides a biochemical explanation for why FLT3-mutant leukemia may be particularly sensitive to the treatment.

Analysis of samples from AML patients offered additional clues about resistance. Leukemia samples that had become resistant to gilteritinib frequently showed increased activity in genes involved in selenoprotein production. The pattern suggests that resistant cells may survive by strengthening the very protective pathway that FLT3 inhibitors weaken. By increasing their capacity to synthesize GPX4 and related proteins, the cells could restore their ability to control lipid peroxidation even while FLT3 signaling remains suppressed. This observation raises the possibility that the selenoprotein pathway could serve as a biomarker of resistance or a target for combination therapies.

The researchers also identified a potential influence outside the cancer cell itself: dietary vitamin E. Vitamin E is an antioxidant that can limit lipid oxidation, and experiments showed that dietary supplementation markedly reduced the effectiveness of gilteritinib in animal models. The result does not establish that ordinary dietary intake compromises treatment, nor does it provide a basis for patients to change supplements without medical advice. It does, however, highlight the importance of understanding how antioxidants may affect therapies that depend on oxidative damage to eliminate cancer cells. High-dose vitamin E supplementation could theoretically suppress the ferroptotic mechanism activated by FLT3 inhibition.

The findings position ferroptosis as a possible therapeutic lever in FLT3-mutant AML and suggest several avenues for future research. Drugs that further weaken GPX4 activity, disrupt selenium metabolism or increase lipid peroxidation might enhance the effects of FLT3 inhibitors, particularly in resistant disease. At the same time, any such approach would require careful dosing because ferroptosis-related processes also occur in normal tissues. The study was conducted by scientists from Baylor College of Medicine, the University of Texas MD Anderson Cancer Center, Texas A&M University and Washington University School of Medicine, with support from federal, philanthropic and Texas-based research programs. Further clinical studies will be needed to determine whether manipulating ferroptosis can improve outcomes for people with AML.

Subject of Research: FLT3-mutant acute myeloid leukemia, ferroptosis and resistance to FLT3 inhibitors.

News Publication Date: Aug. 7, 2026.

Web References: Nature Cell Biology; https://doi.org/10.1038/s41556-026-02016-5

References: DOI: 10.1038/s41556-026-02016-5.

Keywords: acute myeloid leukemia, AML, FLT3, FLT3 inhibitors, gilteritinib, ferroptosis, GPX4, selenoproteins, lipid peroxidation, cancer therapy, drug resistance, vitamin E, leukemia research

FLT3 mutations, particularly internal tandem duplications (ITDs), represent a major driver mutation present in nearly a third of AML cases. These mutations hyperactivate the FLT3 receptor tyrosine kinase, promoting uncontrolled proliferation and survival of leukemic cells. While FLT3 inhibitors have been a cornerstone of targeted therapy, their clinical potential is often curtailed by both intrinsic and acquired resistance mechanisms, resulting in frustratingly transient remissions. The crux of the current challenge lies in decoding and circumventing the cellular processes that blunt the efficacy of these drugs.

Enter autophagy — a cellular recycling program crucial for maintaining homeostasis under stress conditions. Paradoxically, autophagy can act as a double-edged sword in cancer, sometimes suppressing tumorigenesis, yet in other contexts sheltering malignant cells from therapeutic insults. The study by Albuquerque de Melo et al. meticulously dissects how autophagy acts as a protective lifeline for FLT3-ITD AML cells during FLT3 inhibition, enabling them to survive and adapt despite the drug assault.

Using comprehensive molecular and cellular assays, the authors demonstrate that blocking autophagy markedly enhances the cytotoxicity of FLT3 inhibitors. This combinatorial approach effectively disrupts leukemic cell survival pathways, leading to increased apoptosis and impaired clonogenic potential. Notably, this strategy not only augments initial responses but also suppresses the emergence of resistant clones, a paramount hurdle in AML treatment.

What sets this study apart is its integration of pharmacological and genetic tools to inhibit key autophagy regulators, confirming that autophagy is more than an epiphenomenon in drug resistance. For instance, the use of clinically relevant autophagy inhibitors, in conjunction with established FLT3 kinase inhibitors, triggers synergistic cell death in a spectrum of AML cell lines and primary patient samples harboring FLT3-ITD mutations. This dual targeting approach represents a significant leap towards personalized therapeutics tailored to the molecular Achilles’ heel of this leukemia subtype.

Delving deeper, the investigation explores the mechanistic underpinnings that confer autophagy’s protective shield. It reveals that upon FLT3 inhibitor treatment, AML cells activate a compensatory metabolic and stress response via autophagy, clearing damaged organelles and maintaining mitochondrial integrity. Interrupting this process leads to accumulation of reactive oxygen species and metabolic collapse, tipping cells into cell death. This elegant mechanistic insight provides a rational basis for clinical evaluation of autophagy blockade in combination with FLT3-directed therapy.

The implications of these findings extend far beyond FLT3-ITD AML. They exemplify a broader paradigm wherein adaptive stress responses in cancer cells can be exploited to amplify treatment efficacy. Autophagy, long considered a complex and sometimes confounding element in oncology, emerges here as a tangible and actionable target. This study redefines the therapeutic landscape, suggesting that overcoming drug resistance may require dismantling the very cellular lifelines that cancer cells deploy under pharmacological pressure.

Moreover, this research aligns with a growing recognition that monotherapies targeting single oncogenic drivers frequently fall short due to the dynamic adaptability of cancer cells. Multimodal approaches that combine targeted agents with inhibitors of cellular stress pathways like autophagy represent a future-proof strategy to outmaneuver cancer’s plasticity. The preclinical evidence provided by Albuquerque de Melo et al. paves the way for clinical trials combining autophagy inhibitors and FLT3-targeted drugs, potentially setting a new standard of care for patients with FLT3-ITD AML.

Critically, the study also addresses the safety and feasibility of autophagy inhibition, acknowledging that systemic blockade of autophagy carries risks owing to its physiological roles. The authors suggest that selective targeting within the cancer context and careful dose optimization will be crucial for minimizing adverse effects in clinical applications. This nuanced perspective balances optimism with pragmatism, underscoring the need for rigorous translational research.

In the context of personalized medicine, the identification of biomarkers predicting response to autophagy modulation could revolutionize patient stratification. By harnessing molecular profiling to pinpoint AML patients most likely to benefit, clinicians can deliver more effective, less toxic regimens. This precision approach dovetails seamlessly with the rising tide of targeted therapies that are reshaping hematologic oncology.

As the scientific community digests these compelling findings, the study serves as a beacon for drug development pipelines targeting refractory AML and perhaps other hematological malignancies. It challenges researchers and clinicians alike to rethink therapeutic strategies, not merely in terms of hitting cancer drivers but also dismantling the cellular fortresses cancer erects to survive.

Looking ahead, the integration of autophagy inhibition with FLT3 inhibitor therapy holds transformative potential. Enhanced understanding of the interplay between oncogenic signaling and cellular stress responses will undoubtedly expand the therapeutic arsenal against AML. With resistance mechanisms becoming increasingly illuminated, rational combination therapies such as this may finally translate into durable remissions and improved survival outcomes.

In summary, the work of Albuquerque de Melo and colleagues delivers a paradigm-shifting concept: targeting autophagy can break the spell of FLT3 inhibitor resistance in AML, breathing new life into treatment prospects. This multidimensional approach combining molecular insights, translational relevance, and clinical foresight stands to impact the lives of countless patients who currently face limited options. The horizon for AML therapy just brightened, promising a new chapter in the conquest of this formidable disease.

Subject of Research: Acute myeloid leukemia (AML), FLT3-ITD mutations, drug resistance, autophagy inhibition, targeted cancer therapy.

Article Title: Autophagy inhibition potentiates the antileukemic effect of FLT3 inhibitors and overcomes resistance in FLT3-ITD acute myeloid leukemia.

Article References: Albuquerque de Melo, M., Santos de Macedo, B.G., Pereira-Martins, D.A. et al. Autophagy inhibition potentiates the antileukemic effect of FLT3 inhibitors and overcomes resistance in FLT3-ITD acute myeloid leukemia. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03037-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03037-7